+390677209020 | +39 0267380552 info@direnzo.biz | sedemilano@direnzo.biz | Italian Language
EU-QPPV and UK-QPPV

EUQPPV, UKQPPV, and related pharmacovigilance activities

European legislation and Good Pharmacovigilance Practices (GVPs) require companies holding a Marketing Authorization (MA) for medicinal products for human use in EU Member States to have a permanent and continuous EU Qualified Person Responsible for Pharmacovigilance (EU-QPPV) at their disposal.  Similarly, UK regulations require MA Holders of medicinal products for human use in the UK to have a UK-QPPV residing and operating in the UK or EU/EEA, who is responsible for the establishment and maintenance of the pharmacovigilance system for products authorized in the UK.  The QPPV is responsible for overseeing all pharmacovigilance activities carried out, in accordance with legislation. Di Renzo Regulatory Affairs has a dedicated pharmacovigilance unit, with numerous experts with the adequate training and experience to undertake the roles of EU-QPPV, UK-QPPV, and Deputy.

In this field, the main services offered are:

  • Assuming the role of Qualified Person Responsible for Pharmacovigilance in the EU (EU-QPPV) – including the availability of a Deputy
  • Assuming the role of Qualified Person Responsible for Pharmacovigilance in the UK (UK-QPPV) – including the availability of a Deputy
  • Management of the entire pharmacovigilance quality system and assuming the role of Pharmacovigilance Quality Assurance Responsible
  • Screening of adverse reaction reports from EudraVigilance and case management 
  • Screening of Italian and international scientific literature for medicinal products and active substances
  • Medical assessment of adverse reaction reports
  • Follow-up management
  • Data Entry and Quality Control of adverse reaction reports in the Safety Database
  • Submission of ICSRs to the Competent Authorities
  • Exchange of safety information with commercial Partners, including any Local Responsible for Pharmacovigilance/Local Contact Points and UK National Contact Person for Pharmacovigilance (NCP)
  • Preparation and maintenance of the Pharmacovigilance System Master File (PSMF) 
  • Preparation of Periodic Safety Update Reports (PSURs) 
  • Preparation of Risk Management Plans (RMPs) 
  • Drafting, reviewing, and updating safety agreements (Pharmacovigilance Agreements or Safety Data Exchange Agreements – SDEAs)
  • Periodic review of safety data
  • Signal detection
  • Processing of the adverse reaction report backlog into the Safety Database
  • Entry and updating of medicinal product information in the Product Management Service (PMS)
  • Pharmacovigilance Due Diligence following portfolio expansion due to acquisitions from other MA Holders
  • Periodic training for the MA Holder’s internal staff on pharmacovigilance, procedures for sharing adverse reaction reports and applicable pharmacovigilance procedures
  • Periodic training for sale force on pharmacovigilance and procedures for sharing adverse reaction reports
  • Conducting GVP audits to commercial Partners, including Providers, Local Responsible for Pharmacovigilance/Local Contact Points, Distributors, Manufacturers responsible for batch release, etc.